Escitalopram in the treatment of major depressive disorder in primary-care settings: An open-label trial

Depression and Anxiety

Volumn 25, Issue 12, 2008, Pages

  Chokka, Pratap ^a   Legault, Mark ^b  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

^b H LUNDBECK A S   (Denmark)

Author keywords

Antidepressant; Canada; Depression; Primary care; Selective serotonin reuptake inhibitor

Indexed keywords

ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CLINICAL GLOBAL IMPRESSION SCALE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OPEN STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SHORT FORM 36; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PRIMARY HEALTH CARE; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 57349191650     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20458     Document Type: Article

References (49)

1. Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237-247.
2. Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J Clin Psychiatry 2007;68(Suppl. 2):36-41.
3. Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 1996;168(Suppl. 30):38-43.
4. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. J Am Med Assoc 1999;282:1737-1744.
5. Wittchen HU, Pittrow D. Prevalence, recognition and management of depression in primary care in Germany: the Depression 2000 study. Hum Psychopharmacol 2002;17(Suppl. 1):S1-S11.
6. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (depression research in European Society). Int Clin Psychopharmacol 1997;12:19-29.
7. Lesage AD, Goering P, Lin E. Family physicians and the mental health system. Report from the Mental Health Supplement to the Ontario Health Survey. Can Fam Physician 1997;43:251-256.
8. Mojtabai R, Olfson M. Treatment seeking for depression in Canada and the United States. Psychiatr Serv 2006;57:631-639.
9. Bilsker D, Goldner EM, Jones W. Health service patterns indicate potential benefit of supported self-management for depression in primary care. Can J Psychiatry 2007;52:86-95.
10. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21:1659-1668.
11. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217.
12. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64.
13. Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo- controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
14. Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. Br J Psychiatry 2001;(Suppl. 42):S9-S17.
15. Kilbourne AM, Valenstein M, Bauer MS. The research-top-ractice gap in mood disorders: a role for the US Department of Veterans Affairs. J Clin Psychiatry 2007;68:502-504.
16. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846.
17. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003;64:1091-1093.
18. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002;159:469-473.
19. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005;162:1370-1372.
20. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-204.
21. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
22. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10.
23. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20):22-33.
24. Montgomery SA, Asberg M. A New Depression Scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
25. Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999;9:259-264.
26. Guy W. ECDEU Assessment manual for psychopharmacology [biometric laboratory, DHEW publication no. (ADM)]. (Rev. ed.) Kensington, MD: George Washington University; 1976: p 218-222.
27. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
28. Olie JP, Tonnoir B, Menard F, Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 2006;24:318-324.
29. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21:159-169.
30. Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry 2004;49(Suppl. 1):17S-26S.
31. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-1244.
32. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, CANMAT Depression Workgroup. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl. 1):38S-58S.
33. Schulberg HC, Katon WJ, Simon GE, Rush JA. Best clinical practice: guidelines for managing major depression in primary medical care. J Clin Psychiatry 1999;60(Suppl. 7):19-26.
34. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 2000;163:265-271.
35. Winkler D, Pjrek E, Moser U, Kasper S. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum Psychopharmacol 2007;22:245-251.
36. Wade A, Despiegel N, Heldbo RE. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006;18:83-89.
37. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002;17:265-271.
38. Lin EH, Von KM, Katon W, Bush T, Simon GE, Walker E, Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
39. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl. 22):30-33.
40. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003;18:133-141.
41. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-1132.
42. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22:1331-1341.
43. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-184.
44. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137.
45. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006;51:823-835.
46. Bland RC, Newman SC, Orn H. Help-seeking for psychiatric disorders. Can J Psychiatry 1997;42:935-942.
47. Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001;3:244-254.
48. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003;289:3095-3105.
49. Moller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 2007; 40:53-57.